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OBJECTIVES The aim of this study was to evaluate whether repetitive measurements of plasma levels of
neurohumoral factors and cytokines before and after additional treatment are useful for
predicting mortality in patients with congestive heart failure (CHF).
BACKGROUND Neurohumoral and immune activation play an important role in the pathophysiology of
CHF. However, the effects of serial changes in these factors on the prognostic value remain
unknown.
METHODS We measured plasma levels of neurohumoral factors and cytokines and left ventricular
ejection fraction (LVEF) before and three months after optimized treatment for CHF in 102
consecutive patients with severe CHF (New York Heart Association class III to IV) on
admission to our hospital. Physicians who were blind to the plasma neurohumoral factors
until study completion treated patients using standard drugs. Patients were monitored for a
mean follow-up period of 807 days.
RESULTS Plasma levels of neurohumoral factors, cytokines and LVEF were significantly improved three
months after optimized treatment. Cardiac death occurred in 26 patients. Among 19 variables
including LVEF, only a high level of brain natriuretic peptide (BNP) and interleukin-6 (IL-6) at
three months after optimized treatment showed significant independent relationships by Cox
proportional hazard analysis with a high mortality for patients with CHF.
CONCLUSIONS These findings indicate that high plasma BNP and IL-6 levels three months after optimized
treatment are independent risk factors for mortality in patients with CHF, suggesting that
sustained high plasma levels of BNP and IL-6 after additional standard treatment were
independent risk factors for mortality in patients with CHF despite improvements in LVEF
and symptoms. (J Am Coll Cardiol 2000;36:1587–93) © 2000 by the American College of
Cardiology
Increased levels of various neurohumoral factors have
been found in patients with chronic congestive heart failure
(CHF) (1–8), and high plasma levels of norepinephrine
(NE), endothelin-1 (ET-1), atrial natriuretic peptide (ANP)
and brain natriuretic peptide (BNP) have been reported to be
significant prognostic predictors (9–15), suggesting an impor-
tant role of neurohumoral activation in the pathogenesis of
CHF. Moreover, recent studies have indicated the potential
role of the immune system in the pathophysiology of CHF
(16–19). Plasma levels of interleukin-6 (IL-6) and tumor
necrosis factor-alpha (TNF-alpha) increased in patients with
CHF (20–22) and have been reported to be significant
prognostic predictors in patients with CHF (22).
In previous reports, the neurohumoral factors and cyto-
kines were obtained by only one point sampling, when the
condition of patients was relatively stable, to evaluate the
prognostic value (2,10–16,22). Although there are several
reports estimating the effect of cardiovascular drugs on
neurohumoral factors and cytokines over two time points
(7,8,23–25), there is no report indicating whether repetitive
measurements of these factors before and after additional
treatment for CHF are useful for predicting mortality.
The results of recent clinical trials evaluating the drug
effect on mortality in CHF strongly suggested the important
role of the activation of neurohumoral factors and cytokines,
but there was no report about the relationship between
changes in neurohumoral factors and prognosis after stan-
dard therapy. Therefore, in this study, we evaluated whether
repetitive measurements of plasma levels of neurohumoral
factors and cytokines before and after optimized treatment
for CHF are useful for predicting morbidity and mortality
for patients with CHF.
METHODS
Patients. One hundred twelve consecutive patients with
chronic severe CHF (New York Heart Association
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[NYHA] functional class III to IV) who were hospitalized
in our institution from January 1995 to January 1999 were
entered into this study. Informed consent was obtained
from all patients for participation in the study according to
a protocol approved by the Committee on Human Investi-
gation at our institution. The 70 men and 42 women ranged
in age from 16 to 83 years (mean age 63.9 6 1.4 years). On
echocardiography, all patients showed left ventricular ejec-
tion fraction (LVEF) measured by the biplane disc summa-
tion method (Simpson’s rule) (26) ,45% (mean LVEF
23.2 6 0.9%) before optimized treatment for CHF. The
cause of CHF was dilated cardiomyopathy in 54 patients,
ischemic heart disease for more than three months since
myocardial infarction (MI) in 39 patients, hypertensive
heart disease in 14 patients and regurgitative valvular heart
disease in 5 patients. Patients with acute MI, renal failure,
infection, chronic inflammatory disease and malignancy
were excluded. Sixty-one patients were in NYHA functional
class III, and 51 patients were in class IV. Thirty-eight
patients had been treated previously with diuretics, 28 with
angiotensin-converting enzyme (ACE) inhibitors, 26 with
digitalis, 16 with beta-adrenergic blocking agents, 13 with
nitrates and 10 with a calcium antagonist (amlodipine).
Study protocol. This is a prospective study; study protocol
is shown in Figure 1. At entry, after at least 30 min of bed
rest in a supine position, blood samples were drawn from
the antecubital vein, and, at the same time, LVEF was
measured by echocardiography. After all patients had been
treated using optimal oral drugs for three months, plasma
levels of neurohumoral factors and cytokines and LVEF
were measured again by the same sonographer before and
three months after additional treatment of CHF in all
patients. Physicians who were blind to the plasma levels of
neurohumoral factors and cytokines until study completion
independently selected the additional drugs and managed
patients by standard regimens, such as improvement of
symptoms, physical examination and pulmonary congestion
on chest X-ray. Stable clinical condition was defined as
stable body weight and the absence of signs of pulmonary or
peripheral congestion (27). If digitalis was titrated, the
serum concentration was between 0.5 and 1.0 ng/ml.
Diuretics were given in flexible dosages on the basis of body
weight and daily diuresis. Angiotensin-converting enzyme
inhibitors and beta-blockers were gradually increased to the
maximal dosage possible. The maximal dosage for enalapril
was 20 mg. The maximal dosage for carvedilol and metpro-
lol were 20 mg and 60 mg/day, respectively. All surviving
patients were monitored for .120 days, for a mean
follow-up period of 807 6 42.3 days (range 120 to 1,568
days). The end points, which were judged independently by
researchers, were cardiac death (worsening CHF, lethal MI
or sudden death) or hospitalization for worsening CHF or
MI.
Measurements of plasma levels of neurohumoral factors
and cytokines. Samples for the assay of plasma ANP,
BNP, ET-1, IL-6 and TNF-alpha levels were transferred to
chilled disposable tubes containing aprotinin (500 kallikrein
inactivator U/ml) and ethylenediaminetetraacetic acid (1
mg/ml). Samples for the assay of plasma NE levels were
transferred to chilled disposable tubes containing ethyl-
enediaminetetraacetic acid (1 mg/ml). The blood samples
were immediately placed on ice and centrifuged at 4°C, and
aliquots of plasma were immediately stored at 230°C until
assay.
Plasma ANP levels were measured with a specific immu-
noradiometric assay for human alpha-ANP using a com-
mercial kit (Shionoria ANP kit, Osaka, Japan) as reported
previously (13). Plasma BNP levels were measured with a
commercially available specific immunoradiometric assay kit
for human BNP (Shionoria BNP kit, Osaka, Japan) as
reported previously (13). Plasma ET-1 levels were measured
by radioimmunoassay as described (7). Plasma NE levels
were measured by high performance liquid chromatography.
Both plasma levels of IL-6 and TNF-alpha measure-
ments were performed using a commercially available im-
munoassay kit (Quantikine HS, R&D Systems, Minneso-
ta). The intraassay coefficients of variation for IL-6 and
TNF-alpha were 3.6% and 6.1%, respectively; the intraassay
coefficients of variation for IL-6 and TNF-alpha were 3.8%
and 7.8%, respectively. The minimal detectable values of
TNF-alpha and IL-6 were 0.12 and 0.0094 pg/ml, respec-
tively. The assay system for IL-6 had no cross reactivity for
other cytokines, including TNF-alpha, and the assay system
for TNF-alpha had no cross reactivity for other cytokines,
including IL-6, as we previously reported (22).
Statistical analysis. All results were expressed as the
mean 6 SEM. Comparison of the LVEF and plasma levels
of ANP, BNP, NE, ET-1, IL-6 and TNF-alpha before and
three months after optimized treatment were made by
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
CHF 5 congestive heart failure
ET-1 5 endothelin-1
IL-6 5 interleukin-6
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
NE 5 norepinephrine
NYHA 5 New York Heart Association
TNF-alpha 5 tumor necrosis factor-alpha
Figure 1. Study protocol.
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Student paired t test. To determine whether repetitive
measurements of plasma levels of neurohumoral factors and
cytokines before and after additional treatment for CHF are
useful for predicting mortality or morbidity and mortality in
CHF patients, 19 variables, as listed below, were entered
into a Cox proportional hazard analysis. Kaplan-Meier
analysis was performed on the cumulative survival and
cardiac event-free rates in patients with CHF stratified into
two groups based on median plasma BNP and IL-6 levels;
the differences between survival and cardiac event-free rate
curves were analyzed by log-rank test. The sensitivity and
specificity of plasma BNP and IL-6 values for predicting
mortality or morbidity and mortality were determined, and
receiver operating characteristic curves were constructed by
plotting sensitivity against (1- specificity). The area under
the curves were calculated and analyzed by one-tailed test.
The optimal compromise between sensitivity and specificity
was determined graphically. A value of p , 0.05 was
considered significant.
RESULTS
Patient characteristics. There were 112 patients enrolled
in this study; however, seven patients died within three
months during optimized treatment (six died of worsening
CHF and one died of cerebral infarction), and three patients
dropped out of the study. As a result, 102 patients could be
followed-up from three months after optimized treatment.
Cardiac death occurred in 26 patients during the follow-up
period; the causes of death were: worsening CHF in 18
patients, sudden death in 6 patients and lethal MI in 2
patients. Twenty-one patients were hospitalized during the
follow-up period; the causes of hospitalization were: wors-
ening CHF in 19 patients and recurrent MI in 2 patients.
Patient characteristics are shown in Table 1.
There was no difference between survivors and nonsur-
vivors in age, gender, NYHA functional class and LVEF
before optimized treatment. The number of patients with
ischemic heart disease among nonsurvivors was greater than
that among survivors. Otherwise, there was no difference
between patients with and without cardiac event in age,
gender, NYHA functional class and LVEF before opti-
mized treatment. The number of patients with ischemic
heart disease among those with a cardiac event was greater
than that among patients without a cardiac event.
Total treatments for CHF and optimized treatments for
patients with CHF are shown in Table 2. There was no
difference between survivors and nonsurvivors treated with
diuretics, digitalis, ACE inhibitors, beta-blockers and cal-
cium antagonists, and there was no difference between
patients with a cardiac event and those without a cardiac
event treated with these agents. The number of patients
treated with nitrates was greater among survivors than it was
among nonsurvivors and among those with a cardiac event
compared with those without a cardiac event. This was most
Table 1. Patient Characteristics in 102 Patients With CHF—Survivors and Nonsurvivors or Patients With Cardiac Event and
Without Cardiac Event
Characteristic
All Patients
(n 5 102)
Survivors
(n 5 76)
Nonsurvivors
(n 5 26)
Cardiac Event (2)
(n 5 55)
Cardiac Event (1)
(n 5 47)
Age (yr) 63.6 6 1.5 62.7 6 1.7 66.3 6 3.3 62.0 6 2.1 65.6 6 2.2
Gender
Male 65 48 (63%) 17 (65%) 36 (65%) 29 (62%)
Female 37 28 (37%) 9 (35%) 19 (35%) 18 (38%)
LVEF (%) 23.0 6 0.9 23.5 6 1.0 21.6 6 1.9 23.7 6 1.3 22.2 6 1.3
NYHA class
III 57 45 (59%) 12 (46%) 29 (53%) 28 (60%)
IV 45 31 (41%) 14 (54%) 26 (47%) 19 (40%)
Etiology
IHD 35 21 (28%) 14 (54%)* 13 (24%) 22 (47%)*
Non-IHD 67 55 (72%) 12 (46%) 42 (76%) 25 (53%)
*p , 0.01 vs. survivors or cardiac event (2).
ACE 5 angiotensin-converting enzyme; Cardiac Event 5 cardiac death (worsening CHF, lethal myocardial infarction or sudden death) and hospitalization for worsening
CHF or myocardial infarction; CHF 5 congestive heart failure; IHD 5 ischemic heart disease; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart
Association.
Table 2. Optimal Treatments for CHF in 102 Patients With CHF During Three Months
All Patients
Before/3 Months
Survivors
(n 5 76)
Nonsurvivors
(n 5 26)
Cardiac Event (2)
(n 5 55)
Cardiac Event (1)
(n 5 47)
Diuretics 35/79 56 (74%) 23 (88%) 40 (73%) 39 (83%)
ACE inhibitors 25/71 54 (71%) 17 (65%) 42 (76%) 29 (62%)
Digitalis 23/55 41 (54%) 14 (54%) 32 (58%) 23 (49%)
b-blockers 15/29 24 (32%) 5 (19%) 17 (31%) 12 (26%)
Nitrates 13/41 24 (31%) 17 (65%)* 16 (29%) 25 (53%)*
Calcium antagonist (amlodipine) 10/22 16 (21%) 6 (23%) 12 (22%) 10 (21%)
*p , 0.05 vs. survivors or cardiac events (2). Abbreviations as in Table 1.
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likely because the number of patients with ischemic heart
disease among nonsurvivors or those with a cardiac event
was greater than that among survivors or those without a
cardiac event.
Plasma levels of neurohumoral factors and LVEF before
and at three months after additional treatment for CHF.
New York Heart Association classification, LVEF and the
plasma levels of ANP, BNP, NE, ET-1, IL-6 at three
months after optimized treatment were significantly im-
proved compared with those before optimized treatment
(NYHA; 3.4 6 0.05 vs. 2.2 6 0.05, LVEF; 23 6 0.9 vs.
32.7 6 1.3%, ANP; 208 6 19 vs. 80 6 7.2 pg/ml, BNP;
917 6 96 vs. 285 6 37 pg/ml, NE; 968 6 84 vs. 431 6 32
pg/ml, ET-1; 4.58 6 0.23 vs. 2.69 6 0.1 pg/ml, IL-6;
15.2 6 2.5 vs. 5.0 6 0.7 pg/ml, p , 0.0001) as shown in
Figure 2. There was no difference in plasma levels of
TNF-alpha before and three months after optimized treat-
ment (6.8 6 0.5 vs. 7.0 6 0.6 pg/ml).
Univariate and multivariate predictors of morbidity and
mortality. Nineteen variables, including clinical factors,
neurohumoral factors, cytokines and LVEF before and
three months after optimized treatment were analyzed using
univariate and stepwise multivariate Cox proportional haz-
ard regression analysis for mortality, as shown in Table 3. By
univariate analysis, 12 clinical and neurohumoral factors
were significant predictors of mortality. According to step-
wise multivariate analysis, only high levels of plasma BNP
and IL-6 at three months after optimized treatment were
significant independent predictors. In this study, the relative
risk ratio of BNP at three months after optimized treatment
was 1.001 (95% confidence interval, 1.001 to 1.002) and
that of IL-6 at three months after optimized treatment was
1.075 (95% confidence interval, 1.036 to 1.117).
Furthermore, the same factors were analyzed using uni-
variate and stepwise multivariate Cox proportional hazard
regression analysis for morbidity and mortality as shown in
Table 4. By univariate analysis, seven clinical and neurohu-
moral factors were significant predictors of morbidity and
mortality. According to stepwise multivariate analysis, only
high levels of plasma BNP and IL-6 at three months after
optimized treatment were significant independent predic-
tors. In this study, the relative risk ratio of BNP at three
months after optimized treatment was 1.001 (95% confi-
dence interval, 1.001 to 1.002), and that of IL-6 at three
Figure 2. Comparison of plasma levels of neurohumoral factors and
cytokines before and three months after optimized additional treatment for
heart failure in patients with congestive heart failure. *p , 0.0001 vs. before
additional treatment for congestive heart failure. ANP 5 atrial natriuretic
peptide; BNP 5 brain natriuretic peptide; NE 5 norepinephrine; IL-6 5
interleukin-6.
Table 3. Univariate and Multivariate Predictors of Mortality of 102 Patients With CHF
According to Survival
Variables Univariate chi-square p Multivariate chi-square p
Age (yr) 1.06 NS 0.24 0.63
Gender (male 5 1) 0.003 NS 0.23 0.63
IHD (yes 5 1) 4.11 0.0427 1.06 0.30
NYHA (before) 1.34 NS 2.25 0.13
NYHA (3 months) 17.4 0.0006 3.46 0.33
LVEF (before) 0.51 NS 1.54 0.22
LVEF (3 months) 6.45 0.0111 0.0001 0.99
ANP (before) 0.63 NS 1.06 0.30
ANP (3 months) 15.6 , 0.0001 0.005 0.95
BNP (before) 5.79 0.0161 2.61 0.11
BNP (3 months) 40.7 , 0.0001 29.1 , 0.0001
NE (before) 1.49 NS 0.17 0.68
NE (3 months) 12.3 0.0005 1.10 0.29
ET-1 (before) 0.42 NS 0.42 0.52
ET-1 (3 months) 4.43 0.0354 0.34 0.56
IL-6 (before) 4.08 0.0435 2.40 0.12
IL-6 (3 months) 18.5 , 0.0001 14.3 0.0002
TNF-alpha (before) 4.09 0.043 0.05 0.82
TNF-alpha (3 months) 6.04 0.014 1.79 0.18
ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide; ET-1 5 endothelin-1; IL-6 5 interleukin-6; NE 5
norepinephrine; TNF-alpha 5 tumor necrosis factor-alpha; other abbreviations as in Table 1.
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months after optimized treatment was 1.049 (95% confi-
dence interval, 1.014 to 1.085).
Kaplan-Meier lifetime analysis. The patients were strati-
fied into two groups based on median plasma level of BNP
(170 pg/ml) and IL-6 (3.0 pg/ml) three months after
optimized treatment, and cumulative survival curves were
constructed according to Kaplan-Meier survival methods.
Survival rates, as elevated by Kaplan-Meier analysis, were
significantly 3.4 times higher in patients with plasma BNP
three months after optimized treatment of ,170 pg/ml (p 5
0.0025) and were significantly 2.5 times higher in patients with
plasma IL-6 three months after optimized treatment of ,3.0
pg/ml (p 5 0.0133) as shown in Figure 3A.
Otherwise, the cardiac event-free curve, as elevated by
Kaplan-Meier analysis, was significantly 5.6 times higher in
patients with plasma BNP three months after optimized
treatment of ,170 pg/ml (p , 0.0001), and they were
significantly 1.9 times higher in patients with plasma IL-6
three months after optimized treatment of ,3.0 pg/ml (p 5
0.016) as shown in Figure 3B.
Comparison of the usefulness of BNP and IL-6 as a
predictor of mortality or morbidity and mortality. Re-
ceiver operating characteristic curves showed a greater area
under the curve for the plasma BNP level than for the
plasma IL-6 level, confirming a significantly better prog-
nostic value of the former in predicting mortality (p , 0.05)
or morbidity and mortality (p , 0.001) (Fig. 4, A and B).
Optimal peptide level was determined as the peptide level at
the point closest to that of perfect separation on each of the
receiver operating characteristic curves; the plasma BNP
level was 240 pg/ml, and plasma IL-6 level was 3.0 pg/ml as
both mortality, and morbidity and mortality.
The sensitivity and specificity of mortality or morbidity
and mortality of the patients with a plasma level of BNP
.240 pg/ml were 73.1% and 73.7% or 70.2% and 89.1%,
respectively. The sensitivity and specificity of mortality or
Figure 3. Kaplan-Meier survival (A) and cardiac event-free rate (B) plots
for 102 patients with congestive heart failure subdivided into two groups
according to the median level of BNP (170 pg/ml) and IL-6 (3.0 pg/ml)
three months after additional treatment for congestive heart failure.
BNP 5 brain natriuretic peptide; IL-6 5 interleukin-6.
Figure 4. Plot showing receiver operating characteristic curves for predic-
tion of mortality (A) and morbidity and mortality (B) for plasma level of
BNP and IL-6. BNP 5 brain natriuretic peptide; IL-6 5 interleukin-6.
Table 4. Univariate and Multivariate Predictors of Morbidity and Mortality of 102 Patients
With CHF According to Cardiac Event-Free
Variables Univariate Chi-Square p Multivariate Chi-Square p
Age (yr) 1.44 NS 0.01 0.93
Gender (male 5 1) 0.15 NS 0.39 0.53
IHD (yes 5 1) 3.70 NS 0.89 0.35
NYHA (before) 0.008 NS 0.13 0.71
NYHA (3 months) 5.91 NS 0.70 0.87
LVEF (before) 0.15 NS 1.41 0.24
LVEF (3 months) 12.0 0.0005 1.81 0.18
ANP (before) 1.02 NS 1.17 0.28
ANP (3 months) 23.7 , 0.0001 1.84 0.17
BNP (before) 3.65 NS 1.62 0.20
BNP (3 months) 34.6 , 0.0001 28.2 , 0.0001
NE (before) 0.23 NS 1.00 0.32
NE (3 months) 7.23 0.0072 0.83 0.36
ET-1 (before) 0.004 NS 0.54 0.46
ET-1 (3 months) 4.70 0.0303 0.25 0.62
IL-6 (before) 0.32 NS 0.11 0.74
IL-6 (3 months) 8.14 0.0043 7.60 0.0059
TNF-alpha (before) 3.46 NS 0.26 0.61
TNF-alpha (3 months) 5.77 0.0163 1.74 0.19
Abbreviations as in Table 3.
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morbidity and mortality of patients with a plasma level of
IL-6 .3.0 pg/ml were 69.2% and 56.6% or 59.6% and
56.4%, respectively. However, the sensitivity and specificity
of mortality or morbidity and mortality of patients with a
plasma level of BNP .240 pg/ml and IL-6 .3.0 pg/ml
were 92.3% and 79.1% or 81.8% and 89.7%, respectively.
DISCUSSION
This study reports for the first time that only high levels of
the plasma BNP and IL-6 three months after optimized
treatment were found to be independent and important
prognostic predictors in patients with CHF, despite im-
provements of LVEF and symptoms. This suggests that
plasma levels of BNP and IL-6 are useful for assessment of
the treatment of individual patients with CHF.
Usefulness of repetitive measurements of neurohumoral
factors and cytokines in patients with CHF. In previous
reports of prognostic predictors in patients with CHF,
neurohumoral factors or cytokines were used with only 1
point sampling (2,8,10–16,22). There were several reports
estimating prognostic predictors in patients with CHF
using noninvasive repetitive measurements by echocardiog-
raphy (27,28); however, to our knowledge, there is no report
estimating prognostic predictors in patients with CHF
using repetitive measurements of neurohumoral factors and
cytokines.
In this study, on stepwise multivariate analysis, only high
levels of the plasma BNP and IL-6 three months after
optimized treatment were significant independent predic-
tors. These results suggested titration of the drug and the
doses needed to decrease plasma BNP and IL-6 levels in
CHF, which may be important for a beneficial outcome in
patients with CHF, and repetitive measurements of plasma
BNP and IL-6 levels may be useful as an index for CHF
treatment. In other words, if plasma levels of BNP and IL-6
remain high three months after a patient has received full
doses of ACE inhibitors and beta-blockers, these patients
may be a high-risk group that requires intensive care.
Motwani et al. (29) reported that the serial change of
BNP is more useful than ANP for predicting the effect of
ACE inhibitors on ventricular remodeling in patients with
acute MI. Angiotensin-converting enzyme inhibitors reduce
the mortality of patients with CHF partly due to the
prevention of left ventricular remodeling, and plasma BNP
is thought to be a useful marker of left ventricular remod-
eling after MI (30). These previous studies may support our
findings—that optimized therapy to decrease plasma BNP
reduces the mortality and morbidity of patients with CHF
who have ischemic heart disease.
Why are plasma levels of BNP and IL-6 at three months
after optimized treatment for CHF independent impor-
tant prognostic predictors for morbidity and mortality in
patients with CHF? We previously reported that indepen-
dent predictors of BNP, mainly from the ventricle, were left
ventricular end-diastolic pressure, ET-1 and NE by multi-
variate analysis among hemodynamic parameters, ET-1 and
NE, suggesting that ET-1 and NE, which stimulate myo-
cardial damage, increase the secretion of BNP directly or
indirectly (24). Therefore, plasma levels of BNP imply the
degree of left ventricular damage or dysfunction more than
that of ANP, and BNP is a more important prognostic
predictor than NE, ET-1 and ANP for patients with CHF.
Interleukin-6 is produced mainly in leukocytes, whereas
partly in cardiac myocytes and increased by catecholamine
(31,32). Interleukin-6 can modify the ventricular function
through increase of nitrate oxide synthase (19), suggesting
that IL-6 also plays an important role in ventricular dys-
function in patients with CHF. In this study, receiver
operating characteristic curves confirmed the significantly
better prognostic value of BNP in predicting mortality, and
morbidity and mortality. However, high plasma BNP levels,
in addition to high IL-6 levels, might be better predictors of
mortality, and morbidity and mortality.
In this study, there was no difference in plasma levels of
TNF-alpha before and three months after optimized treat-
ment. A few studies have prospectively shown that treat-
ment for CHF significantly affected TNF-alpha. Mohler et
al. (23) reported that IL-6 levels were significantly decreased
after 26 weeks in patients treated with amlodipine compared
with placebo; however, TNF-alpha levels did not change
significantly over a 26-week period in patients with CHF
treated with amlodipine. Recently, we reported that plasma
levels of TNF-alpha and IL-6 significantly decreased after
14 weeks in patients with CHF treated with angiotensin II
type 1 receptor antagonist (candesartan cilexetil) compared
with the values determined before treatment (33). These
differences may be explained by differences in the effects of
the drugs; however, future studies with more cases are
needed to clarify these findings.
Study limitations. In this study, all patients were treated
using additional drugs such as digitalis, diuretics, vasodilators,
ACE inhibitors and beta-blockers for three months, as judged
independently by physicians. Due to side effects, such as
hypotension, dry cough or worsening renal dysfunction, not all
patients could be treated with ACE inhibitors, and beta-
blockers were not always given to patients who showed
improvement in CHF after treatments such as diuretics or
ACE inhibitors. Otherwise, optimized treatments were not
randomized; therefore, it may be difficult to evaluate the effects
of specific drugs for CHF on morbidity and mortality. If we
evaluated drug treatments three months after optimized treat-
ment in addition to the other 19 variables on Cox multivariate
analysis, none of the drugs would have been independent
predictors of mortality and morbidity and mortality in this
study. Therefore, our findings indicate that decreased plasma
BNP and IL-6 are more closely associated with decreased
mortality rather than improvement of symptoms and LVEF
after three months, independent of the treatment. This sug-
gests that it would be cost-effective therapy to monitor plasma
BNP during treatment of CHF since CHF patients with low
plasma BNP have a good prognosis independent of the therapy
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administered (15). However, future large and multicenter
studies are needed to investigate our hypothesis.
Conclusions. High plasma BNP and IL-6 levels three
months after optimized treatment for CHF are independent
risk factors for morbidity and mortality of patients with CHF;
moreover, plasma BNP and IL-6 levels three months after
optimized treatment are more useful predictors than the levels
of other neurohumoral factors and cytokines such as NE,
ET-1, ANP and TNF-alpha and LVEF. These findings
suggest that the repetitive measurements of plasma BNP and
IL-6 levels were useful for estimating the effects of treatment
for individual patients with CHF. The assessment of plasma
levels of BNP and IL-6 is simple and cost-effective and can be
repeated and, thus, may be a useful addition to the standard
clinical evaluation of patients with severe CHF.
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